Drug intelligence / Profile preview

Ceraxa Plus

Development stage: Preclinical
Lead developer: PendreaBio
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

Ceraxa Plus is a second-generation nanoliposomal therapeutic platform developed by PendreaBio. It consists of a Ceraxa nanoparticle with a hollow core designed to encapsulate standard-of-care (SoC) chemotherapeutic agents. This formulation aims to combine the cytotoxic effects of the encapsulated chemotherapy with the bioactivity of the Ceraxa nanoparticle itself, which targets the ceramide pathway to induce apoptosis in cancer cells. The platform is currently in preclinical development for the treatment of acute myeloid leukemia (AML) (as PB 2001) and various solid tumors (as PB 2002).

Brand names: Ceraxa Plus
Other names: Ceraxa Plus #1Ceraxa Plus #2

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)PP2A (Protein phosphatase 2A)

Beyond the preview

Go deeper on Ceraxa Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ceraxa Plus.

Explore the full profile